Methods and compositions for treating sleep apnea
AssigneeApnimed, Inc. (Delaware)
InventorsLawrence G. MILLER, Ronald FARKAS
Life of this patent
Estimating the term…
Abstract
In general, the invention relates to pharmaceutical compositions comprising a thyrotropin-releasing hormone (TRH) analog, and methods of treating sleep apnea comprising administering a TRH analog.
Claims31
A method of treating a subject having a condition associated with pharyngeal airway collapse, the method comprising administering to a subject in need thereof an effective amount of a thyrotropin-releasing hormone (TRH) analog selected from the group consisting of taltirelin, montirelin, JTP-2942, DN-1417, RX-77368, rovatirelin, azetirelin, orotirelin, protirelin, posatirelin, and their pharmaceutically acceptable salts or prodrugs.
A TRH analog selected from the group consisting of taltirelin, montirelin, JTP-2942, DN-1417, RX-77368, rovatirelin, azetirelin, orotirelin, protirelin, posatirelin, and their pharmaceutically acceptable salts or prodrugs for use in treating a subject having a condition associated with pharyngeal airway collapse.
A pharmaceutical composition comprising a thyrotropin-releasing hormone (TRH) analog selected from the group consisting of taltirelin, montirelin, JTP-2942, DN-1417, RX-77368, rovatirelin, azetirelin, orotirelin, protirelin, posatirelin, and their pharmaceutically acceptable salts or prodrugs, and optionally a pharmaceutically acceptable carrier, for use in treating a subject having a condition associated with pharyngeal airway collapse
Dependencies are inferred from the claim text.